Verstraeten A, Dequeker J
Ann Rheum Dis. 1986 Oct;45(10):852-7. doi: 10.1136/ard.45.10.852.
Peripheral and axial bone mass and fracture incidence were studied in a group of 104 postmenopausal patients with rheumatoid arthritis (RA). Patients were divided into non-corticosteroid and low dose corticosteroid treated groups after elimination of patients with concomitant disease or therapy which might affect bone mass. Results were compared with those obtained in controls matched for age and sex. Bone mass at the distal radius was significantly reduced compared with that of controls in both patient groups. Axial bone mass, however, was normal in both treatment groups, non-corticosteroid treated patients having even a significantly higher bone mass than controls (p less than 0.05) and corticosteroid treated patients (p less than 0.05). Fracture incidence (vertebral and femoral neck) was significantly (p less than 0.01) higher in corticosteroid treated patients than in the non-corticosteroid treated group. The mean lumbar bone mineral content and the body weight of the fracture group were significantly lower than in the controls. There were no significant differences in biochemical markers of bone turnover between the RA groups.
对104名绝经后类风湿关节炎(RA)患者的外周和轴向骨量及骨折发生率进行了研究。在排除可能影响骨量的合并疾病或治疗的患者后,将患者分为非皮质类固醇治疗组和低剂量皮质类固醇治疗组。将结果与年龄和性别匹配的对照组所得结果进行比较。与对照组相比,两个患者组的桡骨远端骨量均显著降低。然而,两个治疗组的轴向骨量均正常,非皮质类固醇治疗的患者骨量甚至显著高于对照组(p<0.05)和皮质类固醇治疗的患者(p<0.05)。皮质类固醇治疗的患者骨折发生率(椎体和股骨颈)显著高于非皮质类固醇治疗组(p<0.01)。骨折组的平均腰椎骨矿物质含量和体重显著低于对照组。类风湿关节炎组之间的骨转换生化标志物无显著差异。